✨ Your Portfolio is fetched and updated from zerodha.
Mid Pharmaceuticals

Ipca Laboratories Ltd.

IPCALAB

Get real time AI alerts about this company on your WhatsApp!
Market Cap
₹34,608 Cr.
P/E
44.45

Ipca Laboratories Ltd.

  • Ipca Laboratories
  • Ajanta Pharma
  • Gland Pharma
  • TJI Pharma
FAQs on Ipca Laboratories Ltd. Shareprice

Ipca Laboratories has given lower returns compared to its competitors.
Ipca Laboratories has grown at ~3.53% over the last 4yrs while peers have grown at a median rate of 15.54%

Ipca Laboratories is expensive when considering the PE ratio, however latest EV/EBIDTA is < 3 yr avg EV/EBIDTA.
Latest PE of Ipca Laboratories is 44.84, while 3 year average PE is 41.47.
Also latest EV/EBITDA of Ipca Laboratories is 20.5 while 3yr average is 22.77.

View FAQ's On Business
Growth Table
  • Ipca Laboratories Ltd.
  • Ajanta Pharma
  • Gland Pharma
Balance Sheet
  • Ipca Laboratories Ltd.
  • Ajanta Pharma
  • Gland Pharma
Balance Sheet Snapshot
No data available.
Fund Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end
Profit & Loss
  • Ipca Laboratories Ltd.
  • Ajanta Pharma
  • Gland Pharma
Cash Flow
  • Ipca Laboratories Ltd.
  • Ajanta Pharma
  • Gland Pharma
Cash Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
Ratios
= Dominant Factor
  • Ipca Laboratories Ltd.
  • Ajanta Pharma
  • Gland Pharma
Quarterly Results
  • Ipca Laboratories Ltd.
  • Ajanta Pharma
  • Gland Pharma
Reverse DCF
locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF
FAQs on Ipca Laboratories Ltd. Financials

Balance sheet of Ipca Laboratories is strong.
It shouldn't have solvency or liquidity issues.

The debt of Ipca Laboratories is decreasing.
Latest debt of Ipca Laboratories is ₹616 Crs as of Mar-25.
This is less than Mar-24 when it was ₹794 Crs.

Yes, profit is increasing.
The profit of Ipca Laboratories is ₹823 Crs for TTM, ₹738 Crs for Mar 2025 and ₹547 Crs for Mar 2024.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Ipca Laboratories latest dividend payout ratio is 13.76% and 3yr average dividend payout ratio is 17.94%

Companies resources are allocated to majorly unproductive assets like Cash & Short Term Investments, Capital Work in Progress

View FAQ's On Shareholding
Ideas Dashboard
Timeline
Watchlist
Portfolio
Alerts
Research
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech